BRKR Quote, Financials, Valuation and Earnings

Avantor has a net margin of 2.17% compared to Bruker's net margin of 4.08%. Bruker's return on equity of 4.53% beat Avantor's return on equity of 12.61%.

Bruker has a consensus price target of $54.11, signalling upside risk potential of 30.26%. On the other hand Avantor has an analysts' consensus of $16.92 which suggests that it could grow by 31.6%. Given that Avantor has higher upside potential than Bruker, analysts believe Avantor is more attractive than Bruker.

Bruker has a beta of 1.181, which suggesting that the stock is 18.13% more volatile than S&P 500. In comparison Avantor has a beta of 1.047, suggesting its more volatile than the S&P 500 by 4.699%.

Bruker has a quarterly dividend of $0.05 per share corresponding to a yield of 0.48%. Avantor offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Bruker pays 26.7% of its earnings as a dividend. Avantor pays out -- of its earnings as a dividend. Bruker's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Bruker quarterly revenues are $801.4M, which are smaller than Avantor quarterly revenues of $1.6B. Bruker's net income of $17.4M is lower than Avantor's net income of $64.5M. Notably, Bruker's price-to-earnings ratio is 79.93x while Avantor's PE ratio is 12.37x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bruker is 1.82x versus 1.31x for Avantor. Usually stocks with elevated PS ratios are considered overvalued.

Azenta has a net margin of 2.17% compared to Bruker's net margin of -28.21%. Bruker's return on equity of 4.53% beat Azenta's return on equity of -3.48%.

Bruker has a consensus price target of $54.11, signalling upside risk potential of 30.26%. On the other hand Azenta has an analysts' consensus of $33.75 which suggests that it could grow by 5.21%. Given that Bruker has higher upside potential than Azenta, analysts believe Bruker is more attractive than Azenta.

Bruker has a beta of 1.181, which suggesting that the stock is 18.13% more volatile than S&P 500. In comparison Azenta has a beta of 1.637, suggesting its more volatile than the S&P 500 by 63.674%.

Bruker has a quarterly dividend of $0.05 per share corresponding to a yield of 0.48%. Azenta offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Bruker pays 26.7% of its earnings as a dividend. Azenta pays out -- of its earnings as a dividend. Bruker's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Bruker quarterly revenues are $801.4M, which are larger than Azenta quarterly revenues of $143.4M. Bruker's net income of $17.4M is higher than Azenta's net income of -$40.5M. Notably, Bruker's price-to-earnings ratio is 79.93x while Azenta's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bruker is 1.82x versus 2.43x for Azenta. Usually stocks with elevated PS ratios are considered overvalued.

Bio-Rad Laboratories has a net margin of 2.17% compared to Bruker's net margin of 10.93%. Bruker's return on equity of 4.53% beat Bio-Rad Laboratories's return on equity of -29.59%.

Bruker has a consensus price target of $54.11, signalling upside risk potential of 30.26%. On the other hand Bio-Rad Laboratories has an analysts' consensus of $315.33 which suggests that it could grow by 27.53%. Given that Bruker has higher upside potential than Bio-Rad Laboratories, analysts believe Bruker is more attractive than Bio-Rad Laboratories.

Bruker has a beta of 1.181, which suggesting that the stock is 18.13% more volatile than S&P 500. In comparison Bio-Rad Laboratories has a beta of 0.946, suggesting its less volatile than the S&P 500 by 5.431%.

Bruker has a quarterly dividend of $0.05 per share corresponding to a yield of 0.48%. Bio-Rad Laboratories offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Bruker pays 26.7% of its earnings as a dividend. Bio-Rad Laboratories pays out -- of its earnings as a dividend. Bruker's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Bruker quarterly revenues are $801.4M, which are larger than Bio-Rad Laboratories quarterly revenues of $585.4M. Bruker's net income of $17.4M is lower than Bio-Rad Laboratories's net income of $64M. Notably, Bruker's price-to-earnings ratio is 79.93x while Bio-Rad Laboratories's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bruker is 1.82x versus 2.73x for Bio-Rad Laboratories. Usually stocks with elevated PS ratios are considered overvalued.

Revvity has a net margin of 2.17% compared to Bruker's net margin of 6.35%. Bruker's return on equity of 4.53% beat Revvity's return on equity of 3.68%.

Bruker has a consensus price target of $54.11, signalling upside risk potential of 30.26%. On the other hand Revvity has an analysts' consensus of $124.12 which suggests that it could grow by 30.8%. Given that Revvity has higher upside potential than Bruker, analysts believe Revvity is more attractive than Bruker.

Bruker has a beta of 1.181, which suggesting that the stock is 18.13% more volatile than S&P 500. In comparison Revvity has a beta of 0.977, suggesting its less volatile than the S&P 500 by 2.331%.

Bruker has a quarterly dividend of $0.05 per share corresponding to a yield of 0.48%. Revvity offers a yield of 0.3% to investors and pays a quarterly dividend of $0.07 per share. Bruker pays 26.7% of its earnings as a dividend. Revvity pays out 12.74% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

Bruker quarterly revenues are $801.4M, which are larger than Revvity quarterly revenues of $664.8M. Bruker's net income of $17.4M is lower than Revvity's net income of $42.2M. Notably, Bruker's price-to-earnings ratio is 79.93x while Revvity's PE ratio is 40.38x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bruker is 1.82x versus 4.18x for Revvity. Usually stocks with elevated PS ratios are considered overvalued.